Cutting Edge: IL-10–Mediated Tristetraprolin Induction Is Part of a Feedback Loop That Controls Macrophage STAT3 Activation and Cytokine Production
暂无分享,去创建一个
[1] I. Hofacker,et al. Tristetraprolin-driven regulatory circuit controls quality and timing of mRNA decay in inflammation , 2011, Molecular systems biology.
[2] A. Schäffer,et al. Inflammatory bowel disease and mutations affecting the interleukin-10 receptor. , 2009, The New England journal of medicine.
[3] P. Blackshear,et al. Tristetraprolin Is Required for Full Anti-Inflammatory Response of Murine Macrophages to IL-101 , 2009, The Journal of Immunology.
[4] P. Blackshear,et al. The p38 MAPK pathway inhibits tristetraprolin‐directed decay of interleukin‐10 and pro‐inflammatory mediator mRNAs in murine macrophages , 2009, FEBS letters.
[5] L. Castellano,et al. Immunological and Genetic Evidence for a Crucial Role of IL-10 in Cutaneous Lesions in Humans Infected with Leishmania braziliensis1 , 2008, The Journal of Immunology.
[6] Tom R. Mayo,et al. Genome-wide Analysis Identifies Interleukin-10 mRNA as Target of Tristetraprolin* , 2008, Journal of Biological Chemistry.
[7] Werner Müller,et al. Interleukin‐10 derived from macrophages and/or neutrophils regulates the inflammatory response to LPS but not the response to CpG DNA , 2006, European journal of immunology.
[8] P. Blackshear,et al. Interferons limit inflammatory responses by induction of tristetraprolin. , 2006, Blood.
[9] P. Murray. The primary mechanism of the IL-10-regulated antiinflammatory response is to selectively inhibit transcription. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[10] M. Freudenberg,et al. IL-12 family members: differential kinetics of their TLR4-mediated induction by Salmonella enteritidis and the impact of IL-10 in bone marrow-derived macrophages. , 2005, International immunology.
[11] P. Blackshear,et al. Immunological Characterization of Tristetraprolin as a Low Abundance, Inducible, Stable Cytosolic Protein* , 2004, Journal of Biological Chemistry.
[12] K. Asadullah,et al. Molecular mechanisms of interleukin‐10‐mediated inhibition of NF‐κB activity: a role for p50 , 2004, Clinical and experimental immunology.
[13] B. Foxwell,et al. Signal Transducer and Activator of Transcription 3 Is the Dominant Mediator of the Anti-Inflammatory Effects of IL-10 in Human Macrophages , 2004, The Journal of Immunology.
[14] Kotaro Suzuki,et al. IL-4–Stat6 Signaling Induces Tristetraprolin Expression and Inhibits TNF-α Production in Mast Cells , 2003, The Journal of experimental medicine.
[15] Peter J. Murray,et al. Shaping Gene Expression in Activated and Resting Primary Macrophages by IL-101 , 2002, The Journal of Immunology.
[16] Michael Karin,et al. Macrophage Apoptosis by Anthrax Lethal Factor Through p38 MAP Kinase Inhibition , 2002, Science.
[17] I. Udalova,et al. Evidence for a Dual Mechanism for IL-10 Suppression of TNF-α Production That Does Not Involve Inhibition of p38 Mitogen-Activated Protein Kinase or NF-κB in Primary Human Macrophages1 , 2002, The Journal of Immunology.
[18] L. Klareskog,et al. Increased number of interleukin-10-producing cells in systemic lupus erythematosus patients and their first-degree relatives and spouses in Icelandic multicase families. , 1999, Arthritis and rheumatism.
[19] P. Blackshear,et al. Feedback Inhibition of Macrophage Tumor Necrosis Factor-α Production by Tristetraprolin , 1998 .
[20] W Sterry,et al. IL-10 is a key cytokine in psoriasis. Proof of principle by IL-10 therapy: a new therapeutic approach. , 1998, The Journal of clinical investigation.
[21] P. Blackshear,et al. Feedback inhibition of macrophage tumor necrosis factor-alpha production by tristetraprolin. , 1998, Science.
[22] S. Akira,et al. Stat3 activation is responsible for IL-6-dependent T cell proliferation through preventing apoptosis: generation and characterization of T cell-specific Stat3-deficient mice. , 1998, Journal of immunology.
[23] P. Blackshear,et al. Bone marrow transplantation reproduces the tristetraprolin-deficiency syndrome in recombination activating gene-2 (-/-) mice. Evidence that monocyte/macrophage progenitors may be responsible for TNFalpha overproduction. , 1997, The Journal of clinical investigation.
[24] R. Dummer,et al. Interleukin‐10 is a growth factor for human melanoma cells and down‐regulates HLA class‐I, HLA class‐II and ICAM‐1 molecules , 1997, International journal of cancer.
[25] Gregory J. Goodall,et al. Differential Regulation of the Stability of Cytokine mRNAs in Lipopolysaccharide-activated Blood Monocytes in Response to Interleukin-10* , 1996, The Journal of Biological Chemistry.
[26] B. Haynes,et al. A pathogenetic role for TNF alpha in the syndrome of cachexia, arthritis, and autoimmunity resulting from tristetraprolin (TTP) deficiency. , 1996, Immunity.
[27] M. Thompson,et al. Promoter Analysis of Zfp-36, the Mitogen-inducible Gene Encoding the Zinc Finger Protein Tristetraprolin (*) , 1995, The Journal of Biological Chemistry.
[28] M Aguet,et al. Inducible gene targeting in mice , 1995, Science.
[29] K. Rajewsky,et al. Interleukin-10-deficient mice develop chronic enterocolitis , 1993, Cell.
[30] Y. Vodovotz,et al. Contrasting mechanisms for suppression of macrophage cytokine release by transforming growth factor-beta and interleukin-10. , 1992, The Journal of biological chemistry.
[31] C G Figdor,et al. Interleukin 10(IL-10) inhibits cytokine synthesis by human monocytes: an autoregulatory role of IL-10 produced by monocytes , 1991, The Journal of experimental medicine.